Antibody Therapeutics
LightNews LightNews
banner
antibodytx.bsky.social
Antibody Therapeutics
@antibodytx.bsky.social
13 followers 4 following 43 posts
Peer-reviewed, open-access international journal published by Oxford University Press. Indexed by ESCI (IF=4.5), PubMed & Scopus (CiteScore=8.4).
Posts Replies Media Videos
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🚀🚀Practical advice in the development of a lyophilized protein drug product
academic.oup.com/abt/article/...
#ProteinDrugProduct #Device
February 9, 2026 at 6:49 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🚀🚀FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization
academic.oup.com/abt/article/...
#FcRider #Nanoparticle #Antibody
February 5, 2026 at 7:18 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential
academic.oup.com/abt/article/...
#TSLP #Antibody
February 4, 2026 at 6:15 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎇🎇Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/article/...
#Bispecific #T_cell_engager
February 3, 2026 at 8:32 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🔥🔥The process using a synthetic library that generates multiple diverse human single domain antibodies
academic.oup.com/abt/article/...
#Antibody #SyntheticLibrary #SingleDomain
February 2, 2026 at 2:35 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🚀🚀🚀A Glycoengineered Anti-ROR1 Antibody, GE-zilovertamab, Selectively Enhances Antibody-Dependent Cellular Cytotoxicity Against Chronic Lymphocytic Leukemia
academic.oup.com/abt/advance-...
#Antibody #ROR1
January 30, 2026 at 1:21 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯🎯A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis
academic.oup.com/abt/advance-...
#Bispecific #Antibody
January 30, 2026 at 12:47 AM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎆🎆🎆IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy
academic.oup.com/abt/advance-...
#Bispecific #Antibody
January 28, 2026 at 6:09 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Call for Proposals: GPCR-Targeting Antibodies 🧬
Covering discovery, engineering, structure, AI design & translational studies.
🗓 Proposal deadline: Feb 28, 2026
#AntibodyTherapeutics #GPCR #Biologics
January 27, 2026 at 2:16 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press) 🎇📷 Novel Modality | Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design academic.oup.com/abt/article/... #SingleDomainAntibody #LightChainOnly #BispecificAntibody
January 27, 2026 at 1:11 AM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯🎯rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering
academic.oup.com/abt/article/...
#Computational #AntibodyDesign
January 26, 2026 at 5:11 AM
antibodytx.bsky.social
New Article Alert from Antibody Therapeutics(IF=4.5, Oxford University Press)
"Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies" contributed by NIH.
academic.oup.com/abt/article/...
#Antibody #Therapeutics #Cancer #Antigen
January 20, 2026 at 2:28 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎉🎉🏆Papers of the Year Award 2025🏆🎉🎉
1. lnkd.in/eZJPPJ5X
2. lnkd.in/enDwP8hu
3. lnkd.in/eGiSt8V9
4. lnkd.in/eswXcn-P
We warmly congratulate all award-winning authors on their remarkable achievements.
#Antibody #Antibodies #AntibodyTherapeutics
January 19, 2026 at 9:40 PM
antibodytx.bsky.social
New Article Alert from Antibody Therapeutics(IF=4.5, Oxford University Press)
🔥🔥🔥Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/advance-...
#Bispecific #Multispecific #TcellEngager
January 19, 2026 at 4:20 PM
antibodytx.bsky.social
Antibody Therapeutics(IF=4.5, Oxford University Press)
🔥🔥🔥Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate
academic.oup.com/abt/article/...
#SolidTumor #ADC #Antibody
January 11, 2026 at 3:06 PM
antibodytx.bsky.social
New Article Alert: "RO4, a high affinity humanized antibody against the juxta membrane region of mesothelin for targeted cancer therapy" from NIH.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #Cancer #Therapy
RO4, a high affinity humanized antibody against the juxta membrane region of mesothelin for targeted cancer therapy
Statement of Significance We developed RO4, a high-affinity antibody that binds a non-shed juxtamembrane epitope, thereby avoiding interference from shed m
academic.oup.com
November 17, 2025 at 11:29 PM
antibodytx.bsky.social
New article alert: "The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity" from Shanghai Epimab Biotherapeutics.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #NK #Engager
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
Statement of Significance Current NK cell engagers (NKCE) show limited clinical efficacy. We developed a novel tetravalent NKCE platform incorporating a re
academic.oup.com
November 3, 2025 at 11:15 PM
antibodytx.bsky.social
New article alert: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" from Fudan University.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs #Bispecific
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design
AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att
academic.oup.com
October 29, 2025 at 12:23 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights "Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA".
academic.oup.com/abt/article/...
#mAbs #Ab
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA
Statement of Significance: The pharmacokinetic (PK) journey of Efineptakin alfa, a long-acting recombinant human interleukin-7, was explored through the co
academic.oup.com
October 27, 2025 at 10:26 PM
Reposted by Antibody Therapeutics
stonedhshi.bsky.social
A new paper just reached "corrected proof" stage on our journal @antibodytx.bsky.social titled "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design".

doi.org/10.1093/abt/...

#Antibody #SingleDomainAntibody #Bispecific #OpenAccess
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design
AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att
doi.org
October 24, 2025 at 4:43 AM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights "Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research" from Massachusetts General Hospital and Harvard Medical School.
academic.oup.com/abt/article/...
#Antibody #mAb
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Statement of Significance: Photoimmunotherapy (PIT) is a tumor-targeted therapy with minimal off-target effects. Recent advances in technology have expande
academic.oup.com
October 18, 2025 at 12:50 PM
antibodytx.bsky.social
New Article Alert: "Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase".
academic.oup.com/abt/advance-...
#Antibody #Therapeutics
Validate User
academic.oup.com
October 14, 2025 at 10:07 PM
antibodytx.bsky.social
New article alert: "CAR NK cell therapy for solid tumors: potential and challenges" contributed by Yanlin Yu and Mitchell Ho from NIH.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #CAR #Celltherapy
CAR NK cell therapy for solid tumors: potential and challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
October 8, 2025 at 12:50 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights
"The process using a synthetic library that generates multiple diverse human single domain antibodies" contributed by Mark A Tornetta from Tavotek Biotherapeutics.
academic.oup.com/abt/article/...
#Antibody #Therapeutics
October 7, 2025 at 12:48 PM
antibodytx.bsky.social
New Publication Alert: "CAR NK Cell Therapy for Solid Tumors: Potential and Challenges" from National Cancer Institute, National Institutes of Health.
academic.oup.com/abt/advance-...
CAR NK Cell Therapy for Solid Tumors: Potential and Challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
September 15, 2025 at 10:42 PM